MISGAV, ISRAEL and LONDON--(Marketwire - September 13, 2010) - Medgenics (
The conference will include a series of one-on-one meetings with institutional investors. Investors interested in scheduling a meeting with Dr. Pearlman and the management team can facilitate a request by contacting the leslie.wolf-creutzfeldt@grayling.com or alternatively contact their Rodman & Renshaw representative directly.
NOTES TO EDITORS:
Medgenics is a commercial-stage biopharmaceutical Company, developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. The first revenue generating commercial deal with a well known multinational pharmaceutical company was negotiated in late 2009.
For more information please visit: www.medgenics.com
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, business strategy, plans and objectives of management for future operations. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made.
Contact Information:
For further information, contact:
Medgenics, Inc.
Dr. Andrew L. Pearlman
Phone: +972 4 902 8900
Grayling, United States
Leslie Wolf-Creutzfeldt
Investor Relations
Phone: +1 646 284-9472
Email: leslie.wolf-creutzfeldt@grayling.com